Research progress on immune cells in cold ischemia-reperfusion injury of renal allografts
10.12483/j.issn.1009-8291.2026.06.012
- VernacularTitle:免疫细胞在移植肾冷缺血再灌注损伤中的研究进展
- Author:
Kangyu LIU
1
;
Zikai FANG
1
;
Chengcheng YANG
1
;
Jixian LIU
1
;
Junjie ZHANG
1
;
Zongyao FAN
1
;
Bin NI
1
;
Ming ZHENG
1
;
Baixin SHEN
1
Author Information
1. Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210000, China
- Publication Type:Journal Article
- Keywords:
transplanted kidney;
cold ischemia-reperfusion injury;
immune cells;
cellular immunotherapy
- From:
Journal of Modern Urology
2026;31(6):580-585
- CountryChina
- Language:Chinese
-
Abstract:
Cold ischemia-reperfusion injury (CIRI) is a major contributor to delayed graft function and long-term graft failure after kidney transplantation.Its pathogenesis involves multiple mechanisms, including energy metabolism disorders, oxidative stress and sterile inflammatory responses.Increasing evidence indicates that immune cells play a central regulatory role in the initiation and progression of CIRI.Damage-associated molecular patterns released during cold ischemia and reperfusion activate innate immunity, leading to the rapid recruitment of neutrophils, macrophages, dendritic cells and amplification of inflammatory cascades.Subsequently, adaptive immune cells, including T cells and B cells, are activated and further contribute to sustained inflammation, disruption of immune tolerance and graft injury.Through cytokine signaling, chemokine-mediated recruitment and antigen presentation, different immune cell subsets form a complex interactive network that ultimately determines the severity and outcome of CIRI.This review summarizes the roles and mechanisms of innate and adaptive immune cells in renal allograft CIRI, highlights their interconnections, and discusses emerging immune cell-targeted therapeutic strategies, aiming to provide a theoretical basis for improving clinical outcomes in kidney transplantation.
